Background: Endometrial carcinomas accounts for 4-8% of all gynaecological malignancies. Over the past 30 years, many genes which cause cancer have been identified in endometrial carcinoma and hyperplasias. Recently, many studies have shown that the most frequently variable expression gene in endometrial carcinoma is PTEN (Phosphatase and TENsilon homologue) tumor suppressor gene which is mutated in about 30 - 50% of endometrial carcinomas. Identification of inactivated PTEN gene is a very important step in the early diagnosis of endometrial carcinomas and hyperplasias. This study was carried out to evaluate the expression of PTEN in the precursor lesions of endometrial carcinoma in peri-menopausal women with abnormal uterine bleeding. Methods: In this cross sectional study, 3634 samples of endometrial tissue were received in the department during the period of 5 years (Jan 2008 to Dec 2012). Of these formalin fixed and paraffin embedded 100 cases of endometrial hyperplasia from perimenopausal women with abnormal bleeding were retrieved and reviewed. PTEN immunohistochemical staining was done and analyzed. Results: Simple hyperplasia without atypia was the most common precursor lesion in perimenopausal women. PTEN expression was significantly higher in immunoreactivity and intensity in simple hyperplasia without atypia. Complex hyperplasia with atypia showed significantly lower immunoreactivity and intensity of PTEN expression. Conclusion: Our study recommends PTEN expression by immunohistochemistry, in all endometrial hyperplasias in the biopsy specimens which is a simple and cost effective technique when compared to other molecular studies.